Macro partitioning
Ipragliflozin (an SGLT2 inhibitor) improves hepatic steatosis and liver dysfunction in patients with Type 2 Diabetes irrespective of body weight reduction.
If you have Type 2 Diabetes and fatty liver, taking Ipragliflozin (50mg daily) can improve your liver health markers (like ALT) even if you do not lose significant body weight. This suggests the drug helps move fat out of the liver into safer storage areas, offering a specific benefit for liver health independent of weight loss efforts.
Clinically, ipragliflozin improves liver dysfunction in patients with T2DM irrespective of body weight reduction.
Why this rating
Strong evidence from a clinical trial (n=48) with stratified analysis, supported by robust animal models, though the clinical sample size is modest.
Source
Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction
Chikara Komiya et al. · PLoS ONE · 2016
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →